Utility of GLP-1R agonists in diabetes requires long term study

What is the clinical relevance to diabetes treatment of the meta-analysis of the effects of glucagon-like peptide-1 receptor (GLP-1R) agonists on weight loss, given that it included mostly short term studies? Contrary to what was stated in the companion editorial, 2 GLP-1R agonists seem to increase...

Full description

Saved in:
Bibliographic Details
Published in:BMJ 2012-02, Vol.344 (feb28 2), p.e1451; author reply e1459-e1451
Main Author: de Oliveira, Jose Mario Franco
Format: Article
Language:English
Subjects:
Anti-Obesity Agents - therapeutic use
Diabetes
Diabetes mellitus
Glucagon-Like Peptide 1 - analogs & derivatives
Humans
Hypoglycemic Agents - therapeutic use
Overweight - drug therapy
Peptides
Peptides - therapeutic use
Receptors, Glucagon - agonists
Thyroid gland
Venoms - therapeutic use
Weight Loss - drug effects
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:What is the clinical relevance to diabetes treatment of the meta-analysis of the effects of glucagon-like peptide-1 receptor (GLP-1R) agonists on weight loss, given that it included mostly short term studies? Contrary to what was stated in the companion editorial, 2 GLP-1R agonists seem to increase the incidence of pancreatitis and pancreatic and thyroid cancers. 3 Only long term prospective comparative randomised trials against established drug treatment of diabetes will determine their effectiveness and safety in diabetes.
ISSN:0959-8138
1468-5833
1756-1833
DOI:10.1136/bmj.e1451